Profile data is unavailable for this security.
About the company
Acurx Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. It develops antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its research and development (R&D) pipeline include antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile (C. difficile), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE) and drug-resistant Streptococcus pneumoniae (DRSP). Its lead antibiotic candidate, ibezapolstat targets the pol IIIC enzyme. Phase II clinical data validate the efficacy of its lead antibiotic candidate, as well as pol IIIC as an appropriate bacterial target.
- Revenue in USD (TTM)0.00
- Net income in USD-14.58m
- Incorporated2017
- Employees4.00
- LocationAcurx Pharmaceuticals Inc259 Liberty AvenueSTATEN ISLAND 10305United StatesUSA
- Phone+1 (917) 533-1469
- Fax+1 (302) 636-5454
- Websitehttps://www.acurxpharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Janone Inc | 0.00 | -17.10m | 32.05m | 5.00 | -- | -- | -- | -- | -3.52 | -0.4564 | 0.00 | 2.26 | 0.00 | -- | -- | 0.00 | -52.40 | -23.12 | -96.58 | -62.22 | -- | 23.38 | -- | -30.14 | -- | -- | 0.0594 | -- | -- | -- | -313.15 | -- | -- | -- |
Viracta Therapeutics Inc | 0.00 | -51.06m | 32.24m | 40.00 | -- | 2.49 | -- | -- | -1.32 | -1.32 | 0.00 | 0.4686 | 0.00 | -- | -- | 0.00 | -66.88 | -86.35 | -97.91 | -106.38 | -- | -- | -- | -11,853.94 | -- | -141.21 | 0.5798 | -- | -- | -- | -3.78 | -- | -- | -- |
NextCure Inc | 0.00 | -62.72m | 32.65m | 82.00 | -- | 0.2853 | -- | -- | -2.25 | -2.25 | 0.00 | 4.10 | 0.00 | -- | -- | 0.00 | -40.18 | -22.59 | -42.35 | -23.54 | -- | -- | -- | -964.96 | -- | -- | 0.00 | -- | -- | -- | 16.07 | -- | -23.17 | -- |
Mink Therapeutics Inc | 0.00 | -22.46m | 32.97m | 31.00 | -- | -- | -- | -- | -0.6538 | -0.6538 | 0.00 | -0.5219 | 0.00 | -- | -- | 0.00 | -172.59 | -- | -2,317.47 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 19.77 | -- | -- | -- |
Fortress Biotech Inc | 84.51m | -68.67m | 33.08m | 186.00 | -- | 1.15 | -- | 0.3915 | -8.88 | -8.88 | 10.29 | 1.49 | 0.366 | 2.19 | 3.89 | 454,371.00 | -66.76 | -52.50 | -117.74 | -99.46 | 68.45 | 63.17 | -182.40 | -236.94 | 1.26 | -11.31 | 0.9758 | -- | 11.58 | 25.75 | 27.42 | -- | -9.37 | -- |
Acurx Pharmaceuticals Inc | 0.00 | -14.58m | 34.51m | 4.00 | -- | 6.79 | -- | -- | -1.14 | -1.14 | 0.00 | 0.3226 | 0.00 | -- | -- | 0.00 | -170.64 | -- | -243.33 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.55 | -- | -- | -- |
LianBio - ADR | 0.00 | -87.98m | 35.10m | 163.00 | -- | 0.172 | -- | -- | -0.8195 | -0.8195 | 0.00 | 1.89 | 0.00 | -- | -- | 0.00 | -28.62 | -- | -35.22 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 43.82 | -- | -- | -- |
Nuo Therapeutics Inc | 608.53k | -3.17m | 35.39m | -- | -- | 34.06 | -- | 58.16 | -0.0754 | -0.0754 | 0.0145 | 0.0235 | 0.2471 | 0.5609 | 3.55 | -- | -128.78 | -116.16 | -173.76 | -354.84 | 79.28 | 70.02 | -521.17 | -854.53 | 2.01 | -1,002.61 | 0.00 | -- | 442.12 | -14.99 | 0.0095 | -- | -- | -- |
Qsam Biosciences Inc | 0.00 | -5.16m | 35.56m | 4.00 | -- | 176.98 | -- | -- | -1.58 | -1.58 | 0.00 | 0.1863 | 0.00 | -- | -- | 0.00 | -424.48 | -944.58 | -- | -- | -- | -- | -- | -- | -- | -74.82 | 0.011 | -- | -- | -- | 15.04 | -- | -- | -- |
Rapid Micro Biosystems Inc | 22.52m | -52.47m | 36.13m | 193.00 | -- | 0.3465 | -- | 1.60 | -1.22 | -1.22 | 0.5234 | 2.78 | 0.1348 | 1.36 | 4.07 | 116,678.80 | -31.41 | -- | -35.44 | -- | -24.36 | -- | -232.99 | -- | 5.29 | -- | 0.0026 | -- | 31.44 | -- | 13.71 | -- | -- | -- |
Eyenovia Inc | 3.79k | -27.26m | 36.29m | 57.00 | -- | 3.61 | -- | 9,575.78 | -0.6639 | -0.6639 | 0.00009 | 0.1976 | 0.0001 | -- | 0.0031 | 66.49 | -91.15 | -80.31 | -119.11 | -117.70 | 0.00 | -- | -719,290.30 | -680.95 | 2.16 | -15.14 | 0.6135 | -- | -- | -- | 2.68 | -- | 152.20 | -- |
Marker Therapeutics Inc | 3.31m | -14.05m | 36.64m | 8.00 | -- | 2.61 | -- | 11.06 | -1.59 | -0.933 | 0.3753 | 1.58 | 0.1285 | -- | 1.93 | 413,892.50 | -54.49 | -53.74 | -69.03 | -62.25 | -- | -- | -424.20 | -1,438.71 | -- | -- | 0.00 | -- | -5.76 | 74.27 | 28.97 | -- | -- | -- |
Brainstorm Cell Therapeutics Inc | 0.00 | -17.19m | 36.88m | 29.00 | -- | -- | -- | -- | -0.4079 | -0.4079 | 0.00 | -0.0803 | 0.00 | -- | -- | 0.00 | -271.62 | -117.19 | -- | -231.65 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 29.18 | -- | -45.34 | -- |
Vyne Therapeutics Inc | 424.00k | -27.87m | 37.08m | 10.00 | -- | 0.4179 | -- | 87.45 | -6.84 | -7.00 | 0.0413 | 6.29 | 0.0061 | -- | 0.1639 | 42,400.00 | -40.27 | -108.41 | -45.86 | -138.57 | -- | -- | -6,573.82 | -1,907.10 | -- | -- | 0.00 | -- | -11.11 | -47.51 | 17.89 | -- | -- | -- |
NRX Pharmaceuticals Inc | 0.00 | -30.16m | 37.23m | 2.00 | -- | -- | -- | -- | -2.95 | -2.95 | 0.00 | -0.1398 | 0.00 | -- | -- | -- | -182.00 | -120.57 | -- | -168.40 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 24.14 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 31 Dec 2023 | 406.39k | 2.81% |
Prospect Financial Services LLCas of 31 Mar 2024 | 272.85k | 1.89% |
Geode Capital Management LLCas of 31 Dec 2023 | 112.13k | 0.78% |
BlackRock Fund Advisorsas of 31 Dec 2023 | 61.88k | 0.43% |
Susquehanna Financial Group LLLPas of 31 Dec 2023 | 53.55k | 0.37% |
Securities America Advisors, Inc.as of 31 Dec 2023 | 44.00k | 0.30% |
SSgA Funds Management, Inc.as of 31 Dec 2023 | 28.57k | 0.20% |
TD Waterhouse Canada, Inc.as of 31 Dec 2023 | 18.66k | 0.13% |
Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 2023 | 17.15k | 0.12% |
Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Dec 2023 | 16.20k | 0.11% |